Structural variation of centromeric endogenous retroviruses in human populations and their impact on cutaneous T-cell lymphoma, Sézary syndrome, and HIV infection by Kaplan, M. H. et al.
Journal Articles 
2019 
Structural variation of centromeric endogenous retroviruses in 
human populations and their impact on cutaneous T-cell 
lymphoma, Sézary syndrome, and HIV infection 
M. H. Kaplan 
M. Kaminski 
J. M. Estes 
S. D. Gitlin 
J. Zahn 
See next page for additional authors 
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles 
 Part of the Infectious Disease Commons 
Recommended Citation 
Kaplan MH, Kaminski M, Estes JM, Gitlin SD, Zahn J, Elder JT, Tejasvi T, Gensterblum E, McGowan JP, 
Contreras-Galindo R, . Structural variation of centromeric endogenous retroviruses in human populations 
and their impact on cutaneous T-cell lymphoma, Sézary syndrome, and HIV infection. . 2019 Jan 01; 
12(1):Article 5045 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/5045. Free 
full text article. 
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic 
Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara 
Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu. 
Authors 
M. H. Kaplan, M. Kaminski, J. M. Estes, S. D. Gitlin, J. Zahn, J. T. Elder, T. Tejasvi, E. Gensterblum, J. P. 
McGowan, R. Contreras-Galindo, and +7 additional authors 
This article is available at Donald and Barbara Zucker School of Medicine Academic Works: 
https://academicworks.medicine.hofstra.edu/articles/5045 
RESEARCH ARTICLE Open Access
Structural variation of centromeric
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populations and their impact on cutaneous
T-cell lymphoma, Sézary syndrome, and HIV
infection
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Abstract
Background: Human Endogenous Retroviruses type K HML-2 (HK2) are integrated into 117 or more areas of
human chromosomal arms while two newly discovered HK2 proviruses, K111 and K222, spread extensively in
pericentromeric regions, are the first retroviruses discovered in these areas of our genome.
Methods: We use PCR and sequencing analysis to characterize pericentromeric K111 proviruses in DNA from
individuals of diverse ethnicities and patients with different diseases.
Results: We found that the 5′ LTR-gag region of K111 proviruses is missing in certain individuals, creating
pericentromeric instability. K111 deletion (−/− K111) is seen in about 15% of Caucasian, Asian, and Middle Eastern
populations; it is missing in 2.36% of African individuals, suggesting that the −/− K111 genotype originated out of
Africa. As we identified the −/−K111 genotype in Cutaneous T-cell lymphoma (CTCL) cell lines, we studied whether
the −/−K111 genotype is associated with CTCL. We found a significant increase in the frequency of detection of the
−/−K111 genotype in Caucasian patients with severe CTCL and/or Sézary syndrome (n = 35, 37.14%), compared to
healthy controls (n = 160, 15.6%) [p = 0.011]. The −/−K111 genotype was also found to vary in HIV-1 infection.
Although Caucasian healthy individuals have a similar frequency of detection of the −/− K111 genotype, Caucasian
HIV Long-Term Non-Progressors (LTNPs) and/or elite controllers, have significantly higher detection of the −/−K111
genotype (30.55%; n = 36) than patients who rapidly progress to AIDS (8.5%; n = 47) [p = 0.0097].
Conclusion: Our data indicate that pericentromeric instability is associated with more severe CTCL and/or Sézary
syndrome in Caucasians, and appears to allow T-cells to survive lysis by HIV infection. These findings also provide
new understanding of human evolution, as the −/−K111 genotype appears to have arisen out of Africa and is
distributed unevenly throughout the world, possibly affecting the severity of HIV in different geographic areas.
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Background
The Human Endogenous Retrovirus HERV-K HML-2
(HK2), first discovered in teratocarcinoma cell lines [1]
and sequenced in 1986 [2], is one of the most recent
retrovirus groups to have entered the genome of the pri-
mate lineage. They arose through a number of single ex-
ogenous infections of germ line cells over the last 35
million years of primate evolution [3–14]. HK2 provi-
ruses, which use a Lys tRNA as a primer for reverse
transcription, were discovered in human cells due to
their similarity to the Mouse Mammary Tumor Virus
(MMTV). These proviruses have 5′ and 3′ long terminal
repeats (LTRs) that were identical at the time of integra-
tion but accumulated mutations over time. Some HK2
entered the genome after the Homo-Pan divergence
about 6–8 million years ago, and therefore are only
found in either humans or chimpanzees [13]. With time,
most of these integrated proviruses became silenced by
introduction of stop codons, frame shifts, and indels
mutations. One major type of inactivation originated by
recombination between the 5′ and 3′ LTRs of full-length
proviruses, creating hundreds of solo LTRs. Utilizing the
human genome assembly (GRCh37/hg19), early esti-
mates suggested that there are approximately 91
full-length HK2 proviruses and 944 solo LTRs [15]. At
least 11 of these HK2 are polymorphically inserted into
the human genome [5, 10, 12, 13, 15–18]. Mining of
data generated by Next Generation sequencing from the
Cancer Genome Atlas Project and the WGS500 project
uncovered 17 new HK2 proviruses. Some of these HK2
proviruses are present polymorphically in only 2 of 358
individuals studied and some in over 95% of individuals
[19]. More recent mining of data from the 1000 Genome
project and the Human Genome Diversity Project [20]
revealed the existence of 36 more HK2 proviruses, which
were found to be present in < 0.05 to 75% of the differ-
ent populations studied. Five of these sites represented
new solo LTRs. One new HK2 provirus, Xq21.33, has in-
tact ORFs for all viral genes and is polymorphically
present in Pygmy and Nigerian populations [20]. Only
two other nearly intact proviruses, notably K113 [21, 22]
and K115 [23] theoretically could also be able to pro-
duce infectious viral particles, but studies have shown
these viruses are not capable of replication.
Recently, we discovered three new type 1 HK2 en-
dogenous retroviruses, which we named K111, K222,
and a recombinant virus K111/K222 [24–26]. Unlike the
other 117 known proviruses, these newly discovered
proviruses are found in the centromeric and pericentro-
meric regions of the human genome, restricted to 15
specific chromosomes. They are somewhat similar to
K105 [5] and K112 sequences previously reported [27].
K111 proviruses are mostly present in the centromeric
region of chromosomes 21 and 22 [25]. The progenitor
of K111 appears to have integrated before the
Homo-Pan divergence and expanded in copy number
during the evolution of hominids but not the chimpan-
zee. K111 is present in the chimpanzee as one copy in
the telomere of chromosome 7, but it is found in about
5 copies in the Denisovan and Neanderthal genomes
[28–31] and in several hundred copies in modern
humans [25]. Shortly after we discovered K111, we
found another centromeric endogenous provirus that we
named K222, which is present mostly in the pericentro-
meric region of chromosomes 13, 14, and 15 [26]. K222
infected the germ line approximately 25 million years
ago and is present as a single copy in the genomes of
high order primates [26]. K111 and K222 share some
homologous regions, and some recombinant sequences
of these two proviruses exist in the centromeres as well.
It is not yet known how many K111, K222, and recom-
binant K111/K222 proviruses actually exist, but based
on quantitative assays and deep sequencing we have esti-
mated that there may be up to several hundreds to thou-
sands of such proviruses present in the germ line of
modern man [25].
In contrast to the previously known 117 proviruses,
which spread mostly by infection, K111 and K222 provi-
ruses appear to have spread in human centromeres via
homologous recombination [24–26]. K222 lacks the 5′
LTR and gag gene, and is inserted into a pericentromeric
repeat, termed pCER [26]. K111 proviruses have a 5′
and 3′ LTR and mostly inactive gag, pol and env genes.
K111, which is a Type 1 HK2, however, has an intact
ORF for the accessory gene np9 [32–36]. This oncogene
arose after the split of Hominids from old world pri-
mates and is present in gibbons [33], gorillas, orangu-
tans, chimpanzees and humans. It makes a 74 amino
acid protein called Np9, which binds to the ubiquitin lig-
ase MDM2 and inhibits its activity towards p53 [33]. It
also acts as a molecular switch for co-activating
beta-catenin, ERK, Akt and Notch1, and promotes the
growth of human leukemia stem/progenitor cells [34].
Np9 also interacts with the promyelocytic leukemia zinc
finger protein (PLZF), a tumor suppressor and transcrip-
tional repressor [35], as well as with Ligand of numb
protein X (LNX), ultimately increasing the transactiva-
tion activity of Notch and likely affecting tumorigenesis
[36]. Interestingly, there are different forms of np9 tran-
scripts produced by K111 s that come from their differ-
ent sequence variants [32]. While the function of the
canonical Np9 has begun to be elucidated, nothing is
known about the function of Np9 s expressed by K111.
In our original studies of K111, we found that a patient
with Sézary syndrome (Sz), a severe form of cutaneous
T-cell lymphoma (CTCL), was missing K111 proviruses
from her genome. We also discovered that the CTCL
cell line Hut 78, and a derivative of that cell line, H9
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[37], that was developed to grow HIV at high concentra-
tions, was also missing K111, a genotype we refer as
−/−K111 in this study. A −/− K111 genotype would also
indicate that hundreds or thousands of K111 proviruses
are missing from the pericentromeres creating pericen-
tromeric instability, a concept defining the high fre-
quency of deletions in the pericentromeric area of our
genome. As a result, we decided to study whether pa-
tients with CTCL have a −/−K111 genotype. In addition,
we studied the prevalence of the −/−K111 genotype in
human populations and the association of the −/−K111
genotype with disease entities of humans. We also fur-
ther characterized K111 sequences in chromosomes 21
and 22 to better define the heterogeneity of K111 s in
human centromeres.
Methods
Study samples
DNA samples from Human/Rodent somatic hybrid cell
lines (each one containing a single human chromosome)
and their parental rodent cells were obtained from the
NIGMS Human/Rodent Somatic Cell Hybrid Mini Map-
ping Panel # 2 DNA, Coriell Cell Repositories.
DNA samples from people of different genders and
ethnic origins were obtained from the HRC2 Human
Random Control DNA panel 2 (Sigma Aldrich, 96 Cau-
casian people) and from Human variation panels HD03
(Indo Pakistani), HD05 (Middle Eastern), HD07 (Japa-
nese), HD12 (Africans South of the Sahara), HD20 (Rus-
sian Krasnodar), HD21 (Italian), HD22 (Ashkenazi
Jewish), HD32 (Chinese), and samples from Mb pygmy
(NA10492, NA10493, NA10494, NA10495, NA10496)
from the Coriell Cell Repositories; these DNA samples
were previously used in another study [26].
DNA from a cohort of HIV patients was obtained
from the peripheral blood lymphocytes (PBLs) of pa-
tients cared for at the University of Maryland, Baltimore,
MD; North Shore University Hospital, Manhasset, NY;
and the University of Michigan, Ann Arbor. Other sam-
ples from HIV-infected individuals were obtained from
the PBLs and or EBV transformed cells from patients
enrolled in the MACS, a natural history study of men
who reported having sex with men. The study partici-
pants were over age 24 to age 79.
Samples of whole blood and/or PBLs extracted from
whole blood were also obtained from patients with
breast cancer, different lymphomas, cutaneous T-cell
lymphoma (CTCL), chronic lymphocytic leukemia
(CLL), and normal controls at the University of Mich-
igan Health System and the VA Ann Arbor Healthcare
System, Ann Arbor, MI, and/or at North Shore
Hematology/Oncology Associates, East Setauket, NY.
All patients had pathologically confirmed cancers. The
patients in the study were over age 30 to age 82.
DNA from either PBLs and/or PBLs transformed by
EBV from Caucasian patients with known psoriasis was
obtained from a cohort of patients cared for at the Uni-
versity of Michigan Dermatology Department, ages 22 to
73 years. DNA extracted from peripheral blood mono-
nuclear cells (PBMCs) from selected patients with
known lupus erythematosus and with Takayasu arteritis
was obtained from patients in studies at the Division of
Rheumatology, University of Michigan, and Mamara and
Istanbul University in Istanbul, Turkey, ages over 30
years. DNA from PBLs of patients from Nigeria, ages 35
to 72 years, was obtained from a study of patients with
breast cancer in Nigeria conducted at the Institute of
Human Virology, University of Maryland, Baltimore.
All patients with CTCL had biopsy-proven disease,
with biopsies reviewed at the University of Michigan.
Two patients with Sézary syndrome (Sz) were cared for
elsewhere, one at the University of Michigan and the
Dana Farber Hospital, Boston, MA and a second one
(our index case) at Yale University, New Haven, CT and
North Shore University Hospital Manhasset, NY. Pa-
tients considered to have Sz had evidence of circulating
atypical T-cells (Sézary cells) early in disease, which were
usually "CD4+, CD45RO+ with frequent loss of T-cell
surface antigens CD2, CD5, and/or CD7 [38]. Most cir-
culating Sézary cells are CD4+, CD7-, and CD26-. There
was usually a CD4+/CD8+ ratio of > 6, often with
greater than 1000 aberrant cells present in circulation.
Epidermotropism, Pautrier’s abscess, and haloed lym-
phocytes were not common. Classic cutaneous T-cell
lymphoma (CTCL) was defined pathologically as consist-
ing of a proliferation of mature CD4 + CD45RO+ mem-
ory T-cells early in disease. In almost all cases, there was
a confirmatory diagnostic test for T-cell clonality with
alpha/beta or gamma/delta T-cell receptor (TCR) gene
rearrangements [39–43]. Large cell transformation
(LCT) was determined when patients with pre-existing
CTCL showed evidence of a morphologic change in
small to medium sized atypical T-cell lymphocytes to a
large cell variant, usually in > 25% of the lymphocyte
population. These cells are typically CD30+, but can be
also CD30- with usually no more than 75% of these cells
having large cell morphology. These cells often show fol-
liculotropism [44, 45].
We obtained samples from HIV-infected patients
with different rates of disease progression in the
MACS cohort and from other institutions. For the
purposes of this study, we will use the term LTNPs
to include: 1. Elite Controllers (EC), who had a viral
load of less than 50 HIV RNA copies/ml on 2 or
more occasions within 1.5 years in the absence of
therapy (one detectable measurement of less than
1000 copies/ml was allowed between the two sup-
pressed values). 2. Viremic Controllers (VC), who had
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a viral load of less than 2000 HIV RNA copies/ml on
two or more tests within 1.5 years in the absence of
therapy (no viral load spikes were allowed). 3. Other
Long-Term Non-Progressors (LTNPs), patients who
remained AIDS-free without therapy for 15 or more
years. A second category of patients are called Inter-
mediate Progressors, and are people who developed
AIDS 5 to 12 years following seroconversion. The
third category, Rapid Progressors, defines patients
who developed AIDS within 3 years of seroconversion
in the MACs cohort or from transfusion 3 years earl-
ier at our combined institutions. It also includes pa-
tients we call First AIDS who appeared with an
opportunistic infection, a severe neurological disease,
a lymphoma or Kaposi sarcoma, and/or a CD4 count
of less than 200 cells/mL of blood when they were
first seen. In some patients, treatment with
anti-retroviral drugs prevented determining the nat-
ural history of the disease. These samples comprise
our fourth category, which we call “Unclassified”.
Cell lines
The following cells lines were utilized in this study: Hut
78, and derivatives of Hut 78, notably H9 and H9/
HTLVIII. These cell lines were obtained from the AIDS
Research and Reference Reagent Program. Cells were
maintained in RPMI medium and supplemented with
10% fetal bovine serum. Human/Rodent somatic hybrid
cell lines were obtained from a human chromosomal
DNA mapping panel (NIGMS Human/RodentSomatic
Cell Hybrid Mini Mapping Panel # 2 DNA Coriell Cell
Repositories).
DNA extraction
DNA was extracted from PBLs and/or cell lines using
the DNeasy blood and tissue kit™ (Qiagen, http://www.
qiagen.com) or from whole blood or cell lines using the
Gentra Puregene Blood Kit™ (Qiagen).
Detection of K111 insertions
Centromeric K111 s were amplified by PCR with the
primers P1, which binds to K111 flanking centromeric
repeat CER:D22Z3, and primer P4, which binds to the
K111 gag gene to produce a ~ 1.6 Kb amplification prod-
uct [25]. The PCR was carried out using the Expand
Long Range dNTPack PCR kit (Roche Applied Science,
Indianapolis, IN). PCR was performed at a final volume
of 50 μl using an initial step of 92 °C for 2 min, followed
by 35 PCR cycles consisting of denaturation at 92 °C for
15 s, annealing at 55 °C for 30 s, and extension at 68 °C
for 5 min. Amplification products were confirmed by se-
quencing [25].
Walking the 5′ genome of K111
PCR amplification was carried out using the primer P1
that binds to the K111 flanking centromeric repeat
CER:D22Z3 and reverse primers located on the gag, pro,
and pol of HK2, called P4, K111 986R, K111 1584R,
K111 2499R, and K111 3460R. The amplification condi-
tions are the same as those used above.
Long-range amplification and sequencing of K111
Production of K111 long sequences of chromosome 21
and 22 for Pac Bio sequencing were carried out using
the primer set K111 5359F and P2R. Long sequences for
CTCL and HIV samples and cell lines HUT 78 and H9
were produced using a primer set P1 and K111 2499R
that binds to the integration site of K111 and to the gag
region of K111, or a set of primers K111 6353F and P2R
that bind to the env gene of K111 before the splice
donor site of np9 [30] and the 3′ integration site, re-
spectively. Amplifications were carried out with four dif-
ferent bar codes attached to the primer K111 2499R or
to K111 6353F, respectively. Reactions were carried out
in 50 μL using 250–500 ng of total DNA per reaction
with the following conditions: 92 °C for 2 min, and 40 cy-
cles consisting of 92 °C for 15 s, 55 °C for 15 s, and 68 °C
for 5 min using the Expand Long Range dNTPack PCR
kit (Roche Applied Science, Indianapolis, IN).
The bar-coded PCR products were size-selected and
purified using the Blue Pippin gel analyzer. The chromo-
somal products were purified using similar conditions.
Adapters were ligated onto the PCR products and the li-
braries were sequenced using the P6 polymerase kit and
C4 sequencing reagents on a PacBio RS II SMRT DNA
Sequencing System. The sequences were processed using
the PacBio SMRT portal. The sequences were
de-barcoded and processed using the RSReadsOfInsert
software filtering for sequences that pass five times
around each SMRT cell to obtain quality values ~ 99.9%.
Sequences were de-duplicated and the edited sequences
were aligned to the K111 reference genome (Acc No.
GU476554.2) using the RS Resequencing and Quiver v1
parameters. In order to determine sequence variants of
proviruses among human populations we used the
minor variant calling platform in the SMRT portal for
reads aligned to K111 consensus sequence that have
passed five times around each SMRT cell. The sequence
alignments were visualized in the IGV viewer.
Real-time qPCR specific for centromeric K111 and K222
The copy number of K111 found in the cellular DNA
was measured by qPCR using the primer K111 1584F
and a modified primer K111 1701R that has locked nu-
cleic acid (LNA) in the CAA sequence underlined in the
primer sequence below, which is highly specific for K111
to produce a 117 bp product that is readily detected
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using Sybrgreen. This LNA primer detects specific mu-
tations in K111 gag but not other HK2s [25]. The qPCR
was performed using the goTaq® qPCR master mix in a
reaction volume of total 20 μl. The following PCR condi-
tions were used: 10 min at 95 °C, followed by 50 cycles
consisting of 30 s of denaturation at 95 °C, and 15 s of
annealing/hybridization at 60 °C. The PCR reactions
were run over 2 h. The relative K111 copy number was
estimated using serial dilutions of DNA from one patient
with the highest K111 copy number, starting at a con-
centration of 1000 ng per reaction. It was felt that total
human DNA from a +/+K111 CTCL patient would be a
more robust standard than K111 clone DNA. This DNA
was frozen in small aliquots and used once in each run
after defrosting. The specific detection of K111 was veri-
fied by sequencing analysis of the PCR product. The
copy number of K222 in cellular DNA was measured by
qPCR using a probe that specifically discriminates the
K222 pCER-pro boundary as previously described [25].
Statistical analysis
Statistically significant differences in the mean copy
number (K111 and K222 copies/genome calculated by
qPCR in each group) were determined using the Stu-
dent’s t-test. Frequencies of detection of K111 5′ LTR
among the groups were compared by chi-square (X2)
analyses. Two-tailed p values were considered significant
at p < 0.05.
List of primers
P1F: 5′-ACA TTC AGA CCA TGG TAG CCG TGT
-3′
P2R: 5′-ACA GTG CTG TGT GGG TCT GAA TGA
-3′
P4R (K111 986R): 5′-GTA CCT TCA CCC TAG AGA
AAA GCC T -3′
GAPDHF: 5′-TGC ACC ACC AAC TGC TTA GCA
CCC-3′
GAPDHR: 5′-CTT GAT GAC ATC ATA TTT GGC
AGG-3′
K111 1584F: 5′-TCC TTA AGG TCA TAG TGG AGT
TGT TGG TAT AC-3′
K111 1701R LNA: 5′-CAT AAG CAT AGC TTT ATG
CAA AC-3′
K111 1965R: 5′-TCC AGG TGC CAT CGG TTG
CAT-3′
K111 2499R: 5′-TTG AGC AAC ATC TTG GAG
CCT TGC-3′
K111 3460R: 5′-ACT TGC CCA ATA TGC AGC
CTT TCC-3′
K111 6353F: 5′-GAC ATG GGA AAT AGG GAA
GGT AAT A-3′
K111 5359F 5′-TCG GCT CAA AGA GCA GAG ATG
GTT-3′
K111F: 5′-AAG AGC ACC AGG ATG CTT AAT
GCC-3′
K111R: 5′-AGT GAC ATC CCG CTT ACC ATG
TGA-3′
K111P: 5′-FAM-TGC CGG TCC TAA CAG TAG
ACT CAC-BHQ1–3′
K222F: 5′-CAG CGT TCT GGA ATC CTA TGT-3′
K222R: 5′-TGT ATT GTG GTA ACT GGG TAT ATG
T-3′
K222P: 5′-FAM- ACC CAC ATG GCA GTG TTC
TGG ATT-BHQ1–3′
Bar codes used for Pac Bio Sequencing;
B ACATCG, E CACTGT, G GATCTG, J AAGCTA
Results
Detection of a −/−K111 [Δ LTR-gag] genotype in CTCL
patients
As we discovered the −/−K111 genotype in CTCL cells,
we collected DNA from patients with CTCL and Sz (an
aggressive form of CTCL) to determine whether the lack
of centromeric 5′ K111 LTR-gag (−/−K111 genotype) is
prevalent in this disease. DNA from CTCL patients was
screened for the K111 provirus using a forward primer
P1, which binds to the flanking CER:D22Z3 region, and
a reverse primer P4, which binds in K111 gag (Fig. 1a).
This set of primers amplifies centromeric K111 provi-
ruses in 15 human chromosomes [24, 25]. The PCR re-
action amplifies multiple products, but the major band,
which we call the K111 beta band, at a molecular weight
of ~ 1614 bp (Fig. 1b), represents multiple centromeric
K111 proviral sequences from many chromosomes as
determined by cloning and sequencing of this amplifica-
tion product in our previous study [25]. Several CTCL
patients did not show the characteristic broad K111 beta
band (Fig. 1b and c). When the DNA samples lack the
K111 beta band, a non-specific amplification product of
~ 2279 bp is detected, which corresponds to the LTR of
HK2 3p25.3 inserted in chromosome 3, as determined
by sequencing (Fig. 1b and c). Patients with a −/−K111
genotype also do not have the characteristic higher mo-
lecular weight gamma and delta bands, which are other
K111 proviral sequences flanked by longer centromeric
CER elements [25]. A −/− K111 genotype is also seen in
the Hut 78 cell line and derivatives of Hut 78, notably
H9 and H9/HTLVIII (Fig. 1b). We previously showed
that using 4 additional primers that bind to other areas
of the 5′ flanking region of K111 still did not produce
amplification products in −/− K111 cells. This confirmed
that the −/− K111 genotype observed with the primers
P1 and P4 is not the result of mutations in the 5′ flank-
ing area preventing the binding of the P1 primer during
PCR, but is due to absence of K111 provirus [26].
Kaplan et al. BMC Medical Genomics           (2019) 12:58 Page 5 of 18
The patients with CTCL who were in this study were
characteristically much sicker than ordinary CTCL pa-
tients having failed UV light treatments and/or topical
steroids. They ultimately required more invasive therap-
ies (Additional file 1: Table S1 and Additional file 2:
Table S2) to control refractory skin tumors, or they had
developed large cell transformation (LCT), new cancers,
or uncontrolled Sz.
Interestingly, the frequency of detection of the
−/−K111 genotype in these patients was significantly
higher (p = 0.0083) in individuals with CTCL (37.14%; n
= 35) than in those of healthy individuals of the same
Fig. 1 Detection of centromeric K111 in the DNA of CTCL patients and cell lines. a Genomic organization of K111 and K222 and primers
used for PCR are shown with arrows. P1 in the alpha repeat CER: D22Z3 and P4 in K111 gag detect the “+/+ K111 genotype”. K222F is
in the flanking pCER element and K222R binds the pro portion of the K222 provirus. K222P binds to the boundary of the integration site
and pro (b) K111 DNA from PBLs and buccal swabs (BS) from patients with either CTCL or Sézary syndrome or CTCL with large cell
transformation labeled or CTCL that transformed to peripheral T-cell lymphoma labeled C, Sz, C3LCT or PCL respectively was amplified
with primers P1 and P4. A strong band shown by an arrow at mw 1614 bp represents the +/+K111 genotype. Patients Sz1, C1, Sz5, C2,
C4, PCL, and C6, as well as the cell line DNA from HUT78, H9 and H9/HTLVIII, have the −/− K111 genotype and show a 2279 bp product
of HERV-K (HML-2) 3p25.3 amplified non-specifically with the primers P1 and P4 when K111 is not present. Patient SZ4 shows a faint
2279 bp band in her BS while her PBLs have the characteristic 1614 bp band. Bands of higher molecular weight represent other insertions
of K111 into other centromeric repeats [25]. c The DNA from the PBL of selected patients is compared to that from a buccal swab (BS).
Most patients show the same K111 amplification pattern in their PBLs as in their BS, indicating that the K111 is in the germ line. Patient
SZ4 shows a −/−K111 genotype in her BS, while her PBLs derived from her bone marrow donor has a +/+K111 genotype. Patient CD8–1
is a patient with CD8 CTCL who is not part of this study, but illustrates the pattern produced from PCR of the DNA of other non CTCL
patients have using P1 and P4 primers
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ethnicity (15.6%; n = 160) (Table 1), suggesting that a
−/−K111 genotype is associated with severe CTCL. The
frequency of detection of the −/−K111 genotype was sig-
nificantly higher in patients with the progressive stages
of the disease such as Sz (45.5%) [p = .039; n = 11], in
contrast to those that have uncomplicated but still se-
vere CTCL (30.7%).
Some CTCL patients also developed multiple other
cancers, as shown in Additional file 1: Table S1 Patients
who have the −/−K111 genotype had more secondary
cancers (11/13, [84%]) in contrast to those who are +/+
K111, (17/26 [62.9%]), but this was not statistically sig-
nificant (X2: 1.58, p = 0.20; Additional file 1: Table S1).
Patients who are −/−K111 were less likely to have
formed tumor nodules and/or large plaques that require
multiple sessions of radiation therapy (4/13 [30.8%] re-
ceiving 18 treatments) than those with a +/+K111
phenotype (15/26 [52.7%] receiving as many as 59 treat-
ments), but this was not statistically significant (X2: 2.51,
p = 0.1128). During each treatment period of radiation,
patients had from 1 to > 5 areas of skin radiated. On the
other hand, the mortality of −/−K111 patients was
higher (61.5% n = 8) than +/+K111 (34.6% n = 9) and
these patients needed whole body radiation (4/13 30.7%)
vs. (5/26 19.2%) as well as bone marrow transplantation
(2/13 15.3% vs. 3/26 11.5%) to control disease, again all
not statistically different.
Having a −/−K111 is uncommon, and indicates that
K111 proviruses are completely absent from the centro-
meric regions of these CTCL patients, something we
also refer to in this paper as pericentromeric instability.
As we do not know whether or not the K111 genotype
might vary among the cell types of the body, we ob-
tained buccal mucosal swabs (BS) to search for the pres-
ence of K111 in healthy cells from some CTCL patients.
As seen in Fig. 1c, the pattern of detection of the K111
genotype was similar in the buccal mucosal and the per-
ipheral blood lymphocytes (PBLs) DNA, indicating that
the lack of K111 or pericentromeric instability is found
in the germ line of these patients. Of interest, one pa-
tient who had severe Sz, and who received an allogeneic
bone marrow transplant, had a +/+K111 genotype de-
tected in her transplanted peripheral blood lymphocytes
(PBLs) but had a −/−K111 genotype in her buccal muco-
sal cells (Patient SZ4, Fig. 1b and c). We could deduce
then that these +/+K111 PBLs represent the engrafted
cells from her transplant.
Detection of −/−K111 genotype in diverse populations
and medical diseases
To put the loss of K111 s or pericentromeric instability
in CTCL patients in perspective, we were interested in
knowing the prevalence of the −/−K111 genotype in di-
verse populations. To do so, we obtained a panel of
DNA from healthy Caucasian individuals from England
[26] and DNA samples from people of different ethnici-
ties around the world (Table 2). We also collected PBLs
and isolated DNA from healthy Caucasian persons as
well as from African patients from Nigeria and from
Hispanic individuals as shown in Table 2.
We found that the prevalence of the −/−K111 genotype
in healthy Caucasians individuals was 16.11% (n = 180),
which stands in stark contrast to healthy African popula-
tions (n = 127; Table 2), whose prevalence of −/−K111 was
2.36% (p = 0.000169). The prevalence of −/−K111 was
higher in African American individuals (7.6%; n = 39) but
this was not statistically significantly different from the
prevalence in Caucasian HIV patients and or Caucasian
Englishmen. We did not find significant differences in the
prevalence of the −/−K111 genotype in populations from
Asia or Europe compared to Caucasian Englishmen or
Caucasian Americans, except for a slight increase in a
population from Siberia (Table 2). A larger sample will be
needed in order to determine whether a significant in-
crease in the −/−K111 genotype exists in the Siberian
population.
We further evaluated the K111 genotype in a collec-
tion of DNA from Caucasian patients with psoriasis,
Table 1 Frequency of Detection of K111 in DNA from Cutaneous T-cell Lymphoma (CTCL) patients
Disease No. tested −/− K111 Frequency of −/− K111 (%) X2 p value
CTCL Total 35 13 37.14 6.96 0.0083
CTCL 13 4b 30.7 0.32 ns
CTCL + LCT 11 4c 36.4 2.97 0.0423
Sézary Syndrome 11a 5 45.5 4.260 0.0390
Caucasian CTCL 35 13 37.1 8.475 0.003601
African American CTCL 4 0 0 24 ns
Caucasian healthy 160 25 15.6
The table shows the frequency of detection of the −/−K111 genotype in patients with CTCL. This proportion is compared to the prevalence of −/−K111 in a
population of healthy Caucasian individuals. aTwo patients with Sz also developed LCT. Neither of these patients was −/− K111. bOne patient developed
peripheral T-cell lymphoma and a second patient developed Hodgkin Lymphoma.cOne patient developed concomitant Hodgkin Lymphoma. LCT Large cell
transformation, Sz Sézary Syndrome. p values were calculated using a X2 test
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HIV, lupus erythematosus, Takayasu arteritis, breast can-
cer and leukemia/lymphoma to determine whether the
−/−K111 genotype might be associated with other skin
or lymphocytic disorders and/or cancers other than
CTCL. To study the prevalence of a −/−K111 genotype
in a skin disorder other than CTCL, we screened the
DNA samples of Caucasian individuals with psoriasis
who lived in the Michigan area (Table 3). The prevalence
of −/−K111 in these patients was 15.4% (n = 123), similar
to the prevalence in healthy Caucasians. We did not find
differences in the outcome of the −/−K111 genotype in
psoriasis patients compared to the +/+K111 genotype as
judged by nail involvement, the need for biologic or sys-
temic treatment, the age of onset and/or any unique
HLA type.
We were also interested in studying whether the
prevalence of the −/−K111 genotype or pericentromeric
instability might influence the outcome of another T-cell
disorder, notably HIV (Table 3). We screened samples
from Caucasian, African American, and Hispanic patients
enrolled in the Multicenter AIDS Cohort Study (MACS)
and samples from three other institutions using the cat-
egories defined above, i.e. LTNPs, Intermediate Progres-
sors, Rapid Progressors, and unclassified.
Overall, the prevalence of the −/−K111 genotype in
HIV-infected Caucasians was 15.2% (n = 164), similar to
healthy Caucasian individuals. Interestingly, the preva-
lence of the −/−K111 genotype in Caucasian patients
with different presentations of HIV infection was 30.55%
(n = 36) in HIV LTNPs or controllers, 18.75% (n = 32) in
Intermediate Controllers, and 8.5% (n = 47) in Rapid
Progressors (Table 3). A statistically significant difference
was found in the prevalence of detection of the −/−K111
genotype between the group of HIV LTNPs and all
Rapid Progressors (p = 0.0097).
We next evaluated the prevalence of the −/−K111
genotype in other cancers as well as in autoimmune dis-
orders. The prevalence of −/−K111 in Caucasian women
with breast cancer was 9.4% (n = 53) (Table 3) while in
African women with breast cancer it was 1.44% (n = 139)
(Table 4). This difference is likely linked to the ethnicity
rather than the disease, as the prevalence of detection of
the −/−K111 genotype in African patients with breast
cancer is similar to that found in modern healthy
African populations of 2.36% (n = 127), suggesting again
that the −/−K111 genotype originated out of Africa. In
Caucasian patients with systemic lupus erythematosus
and Takayasu arteritis, the prevalence of the −/−K111
genotype was 18.4% (n = 38) and 10% (n = 30), respect-
ively (Table 3), similar to the prevalence in healthy Cau-
casian individuals.
Mapping of centromeric proviruses in CTCL patients
We have shown that K111 is present in 15 different
human centromeres [25], with chromosomes 21 and
22 having the highest number of these proviruses.
Recently, we described the discovery of a second
centromeric HK2 we call K222 that resides in many
Table 2 Frequency of Detection of K111 in DNA from individuals of different ethnic groups
Ethnicity No. tested −/− K111 Frequency of −/− K111 (%) X2 p value
Caucasian 180 29 16.11
English 96 13 13.54
American 64 12 18.75
Italian 10 3 30
Ashkenazi 10 1 10
African total 127 3 2.36 14.1415 0.000169*
South Sahara 9 0 0 1.65 ns
Pygmy 5 0 0 0.921 ns
Nigerian 113 3 2.65 12.1039 0.000503*
Asian total 54 12 22.22 1.2288 ns
Asian (MACS) 25 6 24 1.0872 ns
Chinese 10 2 20 0.0506 ns
Japanese 10 1 10 0.3408 ns
Southeast Russia 9 3 33.3 1.933 ns
Amerindian (MACS) 21 3 14.3 0.0255 ns
African American 39 3 7.6 1.82 ns
Stars indicate significantly decreased detection of the −/− K111 genotype in Africans, including Nigerian individuals, as compared with the Caucasian population.
p values were calculated using the X2 test
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pericentromeric regions [26]. We were first able to
detect this set of K222 pericentromeric proviruses in
DNA samples from CTCL cells that have the
−/−K111 genotype. K222 has no 5’LTR and has a de-
letion of gag and much of pro (Fig. 1a). K222 shares
a high homology to K111 in the 3′ end of the pro-
virus. The 3’end of K222 has an LTR, but it lacks the
6 base pair target site duplication specific to K111
and is inserted in a pCER element instead of being
inserted in CER:D22Z3 [25, 26].
We wanted to assure ourselves that the centromeric
proviruses that remain in the DNA of CTCL individuals
with the −/−K111 genotype have a provirus pattern simi-
lar to the pattern we previously characterized in healthy
people. To determine the structure of centromere provi-
ruses, we mapped the DNA of individuals, using a set of
primers that specifically amplify centromere K111 and
K222 [25, 26]. We found that in the DNA of CTCL pa-
tients with the −/−K111 genotype, no K111 beta band
(mw 1614 bp) was seen by PCR (Fig. 2) using the primer
pair P1 and P4 as also shown in Fig. 1. Similarly, no
amplification products were seen in the same −/−K111
patients when the DNA was amplified with reverse
primers that bind at bases 1584 in gag and 2499 in pro,
areas which are absent in the K222 genome (Fig. 2).
Amplification products with these primers were readily
seen in an individual with a +/+ K111 genotype. Using
the primer that binds to 3460 of the pro region of both
K111 and K222, a low molecular weight band was barely
visible in the −/−K111 patients, while a strong band at
4240 bp was seen in +/+K111 normal patients. The low
molecular weight band is from K222, which can be de-
tected in both −/− and +/+K111 individuals. These re-
sults indicate that the pattern of genomic composition
Table 3 Frequency of Detection of −/− K111 in DNA in Caucasian patients with different diseases
Disease Origin No. Tested −/− K111 Frequency of −/− K111 (%) X2 P value
Skin Diseases
Psoriasis Michigan 123 19 15.4 0.0017 ns
HIV Infection
HIV LTNP MACS 25 5 20 0.3046 ns
Michigan, New York 11 5 45.5 6.3308 0.0118
Total LTNP 36 11 30.55 4.39
6.691
0.0366
0.0097*
Intermediate MACS 29 6 20.7 0.4593 ns
Michigan, New York 3 0 0 0.554 ns
Total Intermediate 32 6 18.75 0.192 ns
Rapid AIDS MACS 30 3 10 0.6362 ns
New York, Michigan 17 1 5.9 1.16 ns
Total Rapid AIDS 47 4 8.5 1.526 ns
Unclassified New York, Michigan, MACS 49 5 10.2 0.896 ns
Total 164 25 15.2 0.009 ns
Solid tumors
Breast Cancer New York, Michigan 53 2 9.4 1.26 ns
Lymphomas
Hodgkin Michigan 3 0 0 0.554 ns
Mantle cell Michigan 6 1 16.5 0.048 ns
Marginal zone Michigan 5 1 20 0.0699 ns
DLBCL Michigan 17 1 5.9 0.2806 ns
Follicular Michigan 23 3 13.0 0.1034 ns
CLL Michigan 11 2 18.2 0.0506 ns
Total 65 8 12.3 0.406 ns
Autoimmune Disorders
Takayasu Turkey 30 3 10 0.6362 ns
Lupus Michigan 38 7 18.4 0.1772 ns
The star indicates a significant difference of the frequency of detection of the −/−K111 genotype between the LTNP and Rapid AIDS patients
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Fig. 2 5′ Mapping of pericentromeric HERV-K proviruses in CTCL patients. a Schematic representation of the primer sets used to amplify
centromeric HERV-K (HML-2) proviruses by PCR. The genomic structure of centromeric HERV-K (HML-2) proviruses K111 and K222 is shown; the
viral genes gag, pro, pol, env and np9, surrounded by LTRs, are integrated into centromeric repeats (CER:D22Z3). At the time of integration, target
site duplications are produced at each site of the provirus, which in the case of K111 is GAATTC. The forward primer P1 was used in combination
with four reverse primers: P4, 1584, 2499 and 3460 (the numbers correspond to the nucleotide position in reference to K111) that span the HERV-
K (HML-2) gag and pro genes. The product of these primer sets is indicated by the arrows on the right i.e. P4 etc. b K222 provirus is detected by
PCR in the DNA of the CTCL −/−K111 patients only by the primer set P1–3460 (low molecular weight band shown by the arrow), which was
confirmed by sequencing [26]. These DNAs do not produce the expected bands obtained with the 3 reverse primers P4, 1584 and 2499 as
shown in the samples from patients with a +/+K111 genotype. The asterisk indicates a band, shown by sequencing, to be a non-specific PCR
amplification product of HERV-K (HML-2) 3p25.3
Table 4 Frequency of Detection of −/−K111 in DNA from African and African American patients with different diseases
Disease Origin No. Tested −/−K111 Frequency of −/−K111 (%) X2 P value
African
Healthy Nigeria 127 3 2.36
14.583 0.00001#
African Breast Cancer Nigeria 139 2 1.44 0.307 ns
18.2223 0.00002#
Total African 266 5 1.8 0.00001#
HIV/AIDS Michigan, New York 6 1 16.6 0.216 ns
unclassified Michigan, New York 5 0 0 0.564 ns
HIV LTNP Baltimore 18 1 5.6 0.340 ns
DLBCL Michigan 3 1 33 1.41 ns
CTCL Michigan 4 0 0 0.452 ns
Breast Cancer Michigan 3 0 0 0.574 ns
Total African American all diseases 39 3 7.6 1.821 ns
Statistical analysis was determined between healthy individuals and patients of the same ethnicity. # indicates significant differences between healthy Caucasian
individuals and healthy African individuals or African patients with breast cancer
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of centromere proviruses in −/−K111 is the same in all
the CTCL patients studied, as we had previously deter-
mined in CTCL cell lines [25].
Quantitation of K111 and K222 in humans
We were interested in trying to gauge how many copies of
the K111 and K222 proviruses might be in a person’s gen-
ome. This was important in order to elucidate if +/+K111
patients with CTCL may have reduced numbers of K111.
We developed an assay using primers modified with
locked nucleic acids (LNA), which bind with enhanced af-
finity to the target K111 sequence in the gag region of
K111, but not to K222 or other HK2 proviruses [25].
Using this assay, we screened DNA from all of our CTCL
patients, which yielded the results shown in Fig. 3. Pa-
tients with CTCL and, the severe form Sz, had statistically
significantly fewer copy numbers of K111 than did control
subjects. All −/−K111 patients detected with the P1 and
P4 primers (Figs. 1 and 2, Table 1) had an undetectable
proviral load in their genome using the LNA primer assay
system. The inability to detect K111 with the LNA primer
set in the gag region of −/− K111 individuals also indicates
that the failure to detect K111 is not due to some muta-
tion in the CER elements flanking the virus, but is due to
the absence of K111. The K111 LNA assay detected num-
bers of K111 copies in the human population that varied
within a range of 1230 to 58,000 copies/100 pg of DNA
(average 11,220 copies/100 pg of DNA), which corre-
sponds to 78 to 3480 copies/genome in somatic cells.
These numbers of proviruses are similar to the ones previ-
ously estimated in our laboratory [25]. We did not find
statistically significant differences in the number of copies
of K111 in +/+K111 individuals who are healthy or in
those who have CTCL. Only one CTCL patient had 85
copies of K111 proviruses/100 pg of DNA (Fig. 3). None-
theless, the −/−K111 genotype was readily evaluated with
the LNA technology and gave no amplification products.
This suggests that any association of K111 copies with se-
vere CTCL disease and Sz is determined by having a
−/−K111 genotype rather than fewer copies of K111.
We then determined the numbers of K111 proviruses
in HIV-1 infected people in order to investigate whether
HIV LTNPs have fewer copies of K111 proviruses than
HIV Intermediate and/or HIV Rapid Progressors (Fig. 4).
Quantitation of K111 copies using our K111 LNA assay
revealed that in contrast to HIV negative subjects and to
all Rapid Progressors of Caucasian ethnicity, the copy
number of K111 decreases significantly in HIV LTNPs.
However, we did not observe this difference between
HIV LTNPs of African American ethnicity as compared
to their ethnic controls or African American HIV Rapid
Progressors, confirming the observations noted above
(Fig. 4).
Having determined that human populations of differ-
ent ethnicities have two different genotypes of centro-
meric K111 proviruses, +/+K111 or −/−K111, we looked
at centromeric K222 proviruses, which also have mul-
tiple copy numbers in the pericentromeric regions, to
Fig. 3 Copy number of centromeric K111 in different stages of
CTCL. Centromeric K111 was quantitated in the DNA of PBLs by
qPCR using a LNA primer that is highly specific for K111 gag. The
copy number was determined in the same run using a standard
curve generated by dilution of DNA chosen from a CTCL patient
who had the highest levels of K111 measured in our earliest assays.
Note that one CTCL patient had a relatively low copy number while
all the rest of the patients have either high copy numbers of K111
or have a −/−K111 genotype. Note that the DNA from the PBLs of a
patient who had a bone marrow transplant (BMT) had a high copy
number of K111 while her buccal swab (Fig. 1c) is −/− K111. p
values were calculated using a t-test. Statistical significance p < 0.05
(*), p < 0.01 (**)
Fig. 4 Copy number of centromeric K111 in different stages of HIV
progression. K111 proviral copy number was quantitated in DNA
from patients with HIV using qPCR with the LNA primer specific for
K111. AA RP or Caucasian RP represents African American or
Caucasian patients with HIV who are HIV Rapid Progressors (RP).
Note that the copy number of the Caucasian Long-Term Non-
Progressors (LTNPs) was significantly lower than in Caucasian
controls and RPs. p values were calculated using a t-test. Statistical
significance p < 0.05 (*), p < 0.01 (**)
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evaluate whether there is any difference in the numbers
of K222 proviruses in CTCL or HIV populations. We es-
timated the numbers of K222 centromeric proviruses
that exist in 9 human chromosomes to be approximately
8 to 80 copies using an assay we previously described
[26]. Quantitation of K222 revealed that the number of
K222 proviruses does not change significantly between
control subjects, patients with CTCL or other cancers,
or HIV (Fig. 5). While there was variation in the copy
number of K222 in diverse human populations in this
study, no significant changes were seen in any of the dis-
ease subsets as compared to controls.
Genetic variability of K111 proviruses in the human
genome
K111 s exist in the centromeres in up to 15 different
chromosomes, but are mostly found in chromosomes
21 and 22. As K111 s appear to have spread via hom-
ologous recombination in the centromeres at different
times during the evolution of modern humans, one
would expect to see genetic variation of K111 in
chromosomes 21 and 22. We sequenced the K111
PCR fragments amplified from DNA from human/
hamster hybrid cell lines containing human chromo-
somes 21 or 22 and also DNA from patients with
CTCL and HIV using the PacBio platform that can
sequence single DNA fragments up to 15–20,000 bp.
This approach assures that all sequences present in a
PCR fragment represent one of the many K111 provi-
ruses in that PCR product.
DNA sequence analysis revealed that the K111 pro-
viruses have accumulated many sequence mutations
over time (Fig. 6), with many unique to chromosome
21 or 22. The same K111 sequences seen in these hy-
brid cells were also present in DNA isolated from hu-
man DNA samples. This genetic variability is not
some type of recombination that arose in the
hybridization of these human chromosomes within
hamster cells, as the hamster genome lacks HK2 pro-
viruses, and as similar sequences were found in hu-
man DNA. The sequences that were seen had many
shared indels. The numerous indels variations of
K111 s appear to have arisen by homologous recom-
bination over evolutionary time, confirming our previ-
ous observations [24–26].
Genetic variability of K111 in CTCL and HIV patients
To determine the genetic variability of K111 sequences in
CTCL and HIV patients that have either a +/+ or −/−K111
genotype, we performed PacBio Next-Generation-Sequen-
cing of K111 PCR products generated with primer P2R that
binds the 3′ integration site of K111 CER:D22Z3, and primer
6353F that binds the env region of K111. We also amplified
another segment using primer P1 that binds the 5′
CER:D22Z3, and primer 2499R that binds downstream of
the origin of K111 sequence, in the pro region (Fig. 7). Six bp
barcodes were added to the 5′ end of 6353F and to the 3′
end of 2499R in order to distinguish between the sequence
results from different patients.
A squished plot alignment of the K111 sequences
amplified, displaying only indels, revealed a large degree
of sequence variability of K111 proviruses amplified in
each human DNA sample (Additional file 3: Figure S1).
In patients with a +/+K111 genotype, about 200 K111
proviruses with unique sequences were detected. DNA
sequencing also confirmed the lack of K111 proviral se-
quences on the 5′ side of the K111 provirus in −/−K111
samples. In these patients, we were able to amplify a
fragment of the 3′ portion of the centromere provirus,
which may be related to the pericentromeric K222 provi-
ruses, or recombinant K111/K222 proviruses, as previ-
ously reported [25]. Although, as expected, we did not
obtain DNA sequences at the 5′ site of the K111 se-
quence in −/−K111 samples, we did recover non-specific
amplification products of the HK2 provirus 3p25.3
(Additional file 3: Figure S1), validating the observations
shown in Fig. 1.
Looking at the sequences of 3p25.3 from 4 CTCL indi-
viduals generated by our sequencing technology, we
found that only two copies of this provirus existed in
Fig. 5 Copy number of pericentromeric K222 in cancer, HIV, and
control subjects. The proviral copy number of K222 was quantitated
by qPCR using the primers K222F and K222R, and the molecular
probe K222P, which specifically detect K222 and no other HERV-K
proviruses. The copy number of K222 was calculated in the DNA of
the PBLs of control subjects, patients with CTCL, breast cancer (BC),
diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and
HIV. The copy number is an estimate of the approximate number of
copies per genome and was normalized to the levels of gapdh as
described in the methods section. No significant differences were
observed in the mean copy number of K222 in cancer or HIV
patients as compared to the control subjects. ns = not significant
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these individuals per diploid genome, validating the fi-
delity of the PacBio sequencing. In contrast to K111 se-
quences that have many indels, we did not find indels in
HK2 3p25.3 sequences, but only sporadic mutations that
appear to be SNPs representative of each individual
(Additional file 4: Figure S2). This supports the idea that
the multiple mutations in K111 s were not due to PCR
and sequencing artifact, but rather were due to the evo-
lution and spread of K111 throughout the pericentro-
meric area by a process of homologous recombination
[24–26]. DNA sequencing readily validated the existence
of −/− and +/+ K111 genotypes.
Discussion
In this study we show that approximately 15% of Cauca-
sian people lack K111 proviruses in their pericentro-
meric/centromeric region. In contrast, the −/−K111
genotype was rarely seen in individuals from Nigeria and
was not detected in any other sub-Saharan Africans or
Pygmy populations, suggesting that the −/−K111 geno-
type appeared after ancient humans migrated out of Af-
rica [46]. The finding of a −/−K111genotype in 7.6% of
African Americans probably arose through the forcible
translocation of Africans through the slave trade and
then subsequent intermingling with Caucasian and
Amerindian populations over many generations. The
questions arise: Where did the −/−K111 genotype
originate, and how can 15% of Caucasians lack several
hundreds to thousands of copies of these pericentro-
meric proviruses while almost, if not all, African individ-
uals have K111 proviruses?.
In a retrospective study of DNA samples obtained
from Neanderthal and Denisovan, late Pleistocene
Hominins that moved out of Africa between 50,000 to
400,000 years ago, we found a few copies of K111 in
their genomes, suggesting that they already carried K111
out of Africa [25, 28–31]. Thus, the −/−K111 genotype
we have detected in modern humans does not appear to
come from Neanderthals or Denisovan. It is possible
that the −/−K111 genotype was transmitted to early
modern humans out of Africa from other primitive
hominins that lacked K111. However, it is more likely
that some early human who had a +/+K111 genotype in
their genome at some point in evolutionary time may
have lost the 5′ end of K111 through recombination
with K222, a centromere provirus that also lacks the
exact 5′ end [26]. We have found evidence of recombin-
ant K111/K222 provirus sequences in human genomes
using both PCR-sequencing and Pac Bio Next-Genera-
tion-Sequencing studies, suggesting the possibility that
K222 recombination with K111 can delete the 5′ domain
of K111. These individuals could have evolved into
carrying the −/−K111 to different parts of the world.
The evidence suggests that this event did not take place
Fig. 6 PacBio Sequencing of centromeric K111 in Chr 21, 22 and Human DNA. A squished plot of the PacBio sequences generated from the 3′ side of K111 in
the hamster/human chromosome 21 and 22 hybrids, as well as normal human DNA. The squished map only shows indels (black dots) that represent subsets
of K111 proviruses that are different from the deposited K111 sequence. Numerous shared indels can be seen in many of the sequences, suggestive of the
presence of hundreds of unique K111 proviruses in these chromosomes. There appear to be some unique sequences in chromosome 21 compared to
chromosome 22. The squished map of sequences amplified from human DNA display sequence patterns similar to those found in Chr 21 and 22
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in Africa. The worldwide distribution of the −/−K111 is
of great interest, and it is possible that in some isolated
populations we might find many individuals that exclu-
sively have the −/−K111 genotype.
It is of great interest that so many K111 proviruses
exist in the centromeric and pericentromeric area of
the human genome. These K111 s significantly out-
number the proviruses inserted into non-centromeric
regions. They appear to have expanded to such num-
bers by homologous recombination, a mechanism that
created many indels in K111 proviruses. In addition,
there appear to be uniquely different K111 s in
chromosome 21 and 22 which have the bulk of the
K111 s in our genome. How these proviral differences
play a role in disorders of chromosome 21 such as
trisomy 21 and/or disorders of chromosome 22 is
now under investigation. In the genetic disorder tri-
somy 21, we have shown that K111 is reduced, with
some evidence of further recombination events occur-
ring in these patients’ cells [47].
It should be pointed out that a large number of
centromeric proviruses are not unique to man. In fact,
kangaroo species have several endogenous retroviruses
(KERV) in centromeres found in tandem, and are major
integral parts of active centromeres similar to what is
seen with human K111 s [48].
We asked the question about diseases that could be
associated with the −/−K111 genotype, which produces
pericentromeric instability. Our studies show no differ-
ences in the prevalence of the −/−K111 genotype in
Caucasian patients with psoriasis, lupus, Takayasu arter-
itis, breast cancer and/or lymphomas. However, the
prevalence of the −/−K111 genotype was significantly
higher in Caucasian individuals with CTCL. These
CTCL patients with a −/−K111 genotype were more se-
verely affected by complications like Sz and LCT and
more aggressive forms of disease requiring extensive
treatment to control the disease. It is possible then that
pericentromeric instability in Caucasians in some way
contributes to pathogenesis of CTCL in these patients,
and that missing pericentromeric K111 makes the dis-
ease more severe and difficult to control. Therefore, the
−/−K111 genotype appears to be an independent risk
factor in determining treatment outcome for patients
with CTCL. This could be assessed by a prospective
study of patients with CTCL in order to understand
whether there are outcome differences in disease in
−/−K111 vs. +/+K111 patients. Although African and/
or African-American patients can develop severe
CTCL disease, as do Caucasians, a −/−K111 genotype
is less prevalent. We have insufficient data to under-
stand the role of −/−K111 in African American
Fig. 7 Barcoding of Amplicons of K111 in CTCL patients. The diagram depicts the 5′ portion of K111 that was amplified with primers P1F and
2499R, or the 3’portion of K111 amplified with primers 6535F and P2R. DNA samples were bar-coded so that they could be identified when these
PCR amplicons were used for deep sequencing using the PacBio technology as described in Materials and Methods. Strong bands between 3 Kb
to 4 Kb were cut from gels and purified for deep-sequencing analysis. The −/− K111 genotype did not provide an amplicon with P1F and 2499R.
Two samples that did not amplify using the primers 6355F and P2R had likely interference with the barcode used. Using a different barcode,
these samples produced the right amplification products (data not shown)
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patients. Only 4 patients in our cohort were
African-Americans and 2 had severe disease; both had
a +/+K111 genotype. When considering the role of
centromeric K111 s in human disease, as we have
shown, these proviruses may serve as a marker of the
health of the pericentromeric genome [47].
It has been reported that in patients with CTCL there
is overexpression of HERV-K and HERV-W mRNA
compared to healthy individuals, but there was no differ-
ence in expression levels in more advanced disease [49].
We did not assay the extent of expression of K111 s’ pu-
tative gene np9, or spliced variants of this gene [32, 33],
and/or other genes of K111, but the role of expression
of these genes in CTCL is of great interest for future
studies.
In some cases, patients with severe CTCL may require
bone marrow transplantation. It is possible that donors
with a +/+K111 genotype may be more beneficial than a
−/−K111 donor. This could be ascertained by retrospect-
ive studies of outcome in such transplanted patients
where −/−K111 genotyping of donors could be per-
formed. One of our −/−K111 patients received a
+/+K111 genotype donor marrow. She had engraftment
with good control of her disease. Unfortunately, she sub-
sequently died of cardiac complications from earlier
chemotherapy. Screening donors for a +/+K111 geno-
type might result in better control of disease in these
sick patients.
As a group, Caucasian HIV patients have a 15.3%
prevalence of the −/−K111 genotype. However, there is a
statistically significant higher prevalence of −/−K111
genotype in Caucasian/Hispanic patients who are LTNPs
as compared to Rapid Progressors. It is conceivable that
the numbers of centromeric K111 copies in the genome
increases the risk factor of AIDS development, while
missing centromeric K111 can add to better control of
HIV. The low prevalence of −/−K111 in one population
vs. high prevalence of −/−K111 in another population
might also contribute to the differences in rates of
spread of HIV in the world with −/−K111 acting as lim-
iting factor in transmission. Larger studies will be neces-
sary to confirm these results.
We should note that K111 was first discovered in the
blood of HIV infected individuals, the only type of indi-
viduals in whose blood we have found RNA transcripts
of these centromeric proviruses [24, 25]. K111 RNA was
not detected in the blood of healthy individuals or pa-
tients with breast cancer or several types of lymphomas.
We previously observed that HIV upregulates K111 via
Tat protein transactivation of the K111 promoter. In
addition, Tat was found to relax the heterochromatin at
centromeric areas, allowing for transcriptional activation
of K111 sequences [50, 51]. It would be interesting to
study whether the transcriptional activation of K111
affects HIV pathology and disease progression, and
whether not having K111 negatively affects the course of
HIV infection. It is of interest that the −/−K111 cell lines
Hut 78 and H9, which have the CD4 receptor for HIV,
support the growth of HIV, producing high titers of
virus without going through cell lysis. These cell lines
originated from a patient with CTCL and produced suf-
ficient virus to make a successful HIV test for ELISA
and Western Blotting [37, 52]. These cell lines do not
need to be replenished with feeder cells, but continu-
ously produce significant titers of HIV and do not
undergo cell death. How these cells resist cell lysis and
death remains unexplained, but perhaps the −/−K111
genotype plays a role in preventing cellular death.
This study adds to our understanding of how HK2 vi-
ruses may play a role in control of HIV infection. It has
been shown that HK2 gag interacts with HIV gag redu-
cing HIV-1 release and infectivity, thus interfering with
HIV replication [53, 54]. In addition, HIV-1 induces ab-
errant expression of HK2 Env [55]. This allows human
T-cell clones to HK2 and human anti HK2 Env anti-
bodies to eliminate HIV infected cells in vitro [56–59].
In addition, elite controllers were shown to have strong
HK2 antibody as well as cellular responses to HK2 pro-
viding protection against aggressive viral replication [55].
Finally, K111 s are type 1 proviruses that have the abil-
ity to make functional Np9 proteins, similar to other
HK2 Type 1 proviruses. Recent evidence has shown that
K111 can also produce alternative spliced variants of
np9 [32]. The function of Np9 has begun to be eluci-
dated, but the function of Np9 variants is not yet known.
Therefore, K111 encoded Np9 protein variants may play
some important role in T-cell biology and HIV infection.
In the case of CTCL, the absence of K111 np9 variants
may contribute to failure of cells to die and thus to be-
come neoplastic, while in HIV this may provide protec-
tion against T-cell lysis from HIV and result in better
preservation of T-cells as seen in HIV LTNPs. Clearly,
modern humans have hundreds to thousands of copies
of K111, each one with the potential of generating an
Np9 protein or variants of Np9. Greater understanding
of these proteins may be very important for delineating
the function of the T-cell in CTCL and/or in HIV infec-
tion, leading perhaps to better therapies for T-cell
disorders.
Conclusions
Our data indicate that HK2 proviruses in the pericen-
tromeres of several chromosomes, or at least the 5′
portion of their genomes, are deleted in a subset of
modern humans. Considering that ~ 1000 of these
retroelements exist in the pericentromeres, having a
deletion in the 5′ portion of these retroelements indi-
cates that 3400 Kb of pericentromeric sequence is
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missing. Further, it appears that pericentromeric in-
stability is associated with survival of a subset of
CD4+ T-cells, which together contribute to the devel-
opment of neoplastic transformation with concomi-
tant severe CTCL. In another unknown way,
pericentromeric instability allows a different subset of
CD4+ T-cells to survive better in HIV infection
resulting in long term survival.
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